<DOC>
	<DOCNO>NCT02126046</DOCNO>
	<brief_summary>Allo-hematopoietic stem cell transplantation ( HSCT ) way cure β-thalassemia major present . To expand donor pool，we develop haplo-identical HSCT ( Hi-HSCT ) platform . But prior Hi-HSCT use high dose post-transplant Cyclophosphamide patient leukemia , cytopenia post-transplant often develop , consider symptom GVHD . Therefore , investigator add unrelated umbilical cord blood ( UCB ) Hi-HSCT . It report , third-party cell , UCB reduce GVHD.The purpose study determine whether unrelated UCB follow Hi-HSCT improve outcome Hi-HSCT patient β-thalassemia major .</brief_summary>
	<brief_title>Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation Patients With β-thalassemia Major</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<criteria>βthalassemia major &lt; 18 year old Unrelated umbilical cord blood follow Haploidentical HSCT ≥ 18 year old HLA match related donor Unrelated donor transplant Unrelated umbilical cord blood transplant Severe iron overload heart T2*</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cord Blood Transplant</keyword>
	<keyword>Haploidentical HSCT</keyword>
	<keyword>Thalassemia major</keyword>
</DOC>